Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DB2116960: A Randomized, Double-Dummy, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of UMEC/VI (a Fixed Combination of Umeclidinium and Vilanterol) With Tiotropium In Subjects With COPD Who Continue To Have Symptoms on Tiotropium
Brief Summary: The primary objective is to compare the efficacy of UMEC/VI Inhalation Powder (62.5/25 mcg) once-daily with tiotropium (18 mcg) once-daily over 12 weeks for the treatment of subjects with COPD who have received tiotropium and continue to have symptoms while on tiotropium.


Options:
A: Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: GSK573719 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Umeclidinium/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium/Vilanterol 62.5/25 mcg | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 mcg | Intervention Type: DRUG; Name: Umeclidinium/Vilanterol 62.5/25 mcg; Assigned to Arm(s): Umeclidinium/Vilanterol | Intervention Type: DRUG; Name: Tiotropium 18 mcg; Assigned to Arm(s): Tiotropium
C: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
D: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: FF 400 mcg, Drug: UMEC 500 mcg, Drug: UMEC 250 mcg, Drug: VI 100 mcg | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: FF 400 mcg, Drug: UMEC 500 mcg, Drug: UMEC 250 mcg, Drug: VI 100 mcg | Arm Label: Sequence 3; Type: EXPERIMENTAL; Interventions: Drug: FF 400 mcg, Drug: UMEC 500 mcg, Drug: UMEC 250 mcg, Drug: VI 100 mcg | Arm Label: Sequence 4; Type: EXPERIMENTAL; Interventions: Drug: FF 400 mcg, Drug: UMEC 500 mcg, Drug: UMEC 250 mcg, Drug: VI 100 mcg | Intervention Type: DRUG; Name: FF 400 mcg; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4 | Intervention Type: DRUG; Name: UMEC 500 mcg; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4 | Intervention Type: DRUG; Name: UMEC 250 mcg; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4 | Intervention Type: DRUG; Name: VI 100 mcg; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4

Answer: B